Literature DB >> 7113802

The purine metabolism of protozoa.

G H Hitchings.   

Abstract

Protozoa possess a wealth of purine-salvage enzymes, many with unique, or unusual, substrate specificities. As a result, many opportunities for the chemotherapist exist. An exemplification is found in the conversion in schistosomes of allopurinol ribonucleoside to the corresponding ribonucleotide followed by further anabolism to the very toxic 4-aminopyrazolo(3,4-d)pyrimidine 1-ribonucleotide. The same organisms convert another inosine analog, formycin B, to the ribonucleotide, but its inhibitory effects appear to be exercised primarily by inhibition of the organism's adenylosuccinate synthase. A substantial segment of the Phylum Protozoa shows no vestigial traces of ability to synthesize purines de novo although thymidylate synthase appears to be present in many. The absence of other tetrahydrofolate catalyzed reactions suggests that these functions were never acquired.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7113802     DOI: 10.1016/0065-2571(82)90026-7

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN: 0065-2571


  4 in total

Review 1.  Biochemistry of the Leishmania species.

Authors:  R H Glew; A K Saha; S Das; A T Remaley
Journal:  Microbiol Rev       Date:  1988-12

2.  Activity of inosine analogs against Pneumocystis carinii in culture.

Authors:  M S Bartlett; J J Marr; S F Queener; R S Klein; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  The role of gene duplication in the evolution of purine nucleotide salvage pathways.

Authors:  A Becerra; A Lazcano
Journal:  Orig Life Evol Biosph       Date:  1998-10       Impact factor: 1.950

4.  Comparative genomics of nucleotide metabolism: a tour to the past of the three cellular domains of life.

Authors:  Dagoberto Armenta-Medina; Lorenzo Segovia; Ernesto Perez-Rueda
Journal:  BMC Genomics       Date:  2014-09-17       Impact factor: 3.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.